Osimertinib for EGFR‐Mutant Lung Cancer with Brain Metastases: Results from a Single‐Center Retrospective Study

INTRODUCTION. Osimertinib is a third‐generation tyrosine kinase inhibitor, initially approved for epidermal growth factor receptor (EGFR) mutant non‐small cell lung cancer (NSCLC) with T790M acquired resistance, and now approved in the first‐line setting. However, data supporting the use of osimerti...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Xie, Lijia, Nagpal, Seema, Wakelee, Heather A., Li, Gordon, Soltys, Scott G., Neal, Joel W.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2018
Konular:
Lung Cancer
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656518/
https://ncbi.nlm.nih.gov/pubmed/30126856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0264
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller